| 2.59 -0.39 (-13.09%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.62 |
1-year : | 5.67 |
| Resists | First : | 3.96 |
Second : | 4.86 |
| Pivot price | 3.25 |
|||
| Supports | First : | 2.51 |
Second : | 2.08 |
| MAs | MA(5) : | 2.88 |
MA(20) : | 3.31 |
| MA(100) : | 3  |
MA(250) : | 27.7 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 12.2 |
D(3) : | 14.8 |
| RSI | RSI(14): 33.2 |
|||
| 52-week | High : | 67.71 | Low : | 1.98 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ XRTX ] has closed above bottom band by 4.2%. Bollinger Bands are 2.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.84 - 2.87 | 2.87 - 2.88 |
| Low: | 2.47 - 2.49 | 2.49 - 2.51 |
| Close: | 2.56 - 2.6 | 2.6 - 2.62 |
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Tue, 23 Apr 2024
Closing Bell: Xortx Therapeutics Inc up on Wednesday (XRTX) - The Globe and Mail
Mon, 22 Apr 2024
Closing Bell: Xortx Therapeutics Inc flat on Monday (XRTX) - The Globe and Mail
Sun, 21 Apr 2024
Money Talk Radio with Ellis Martin: XORTX Therapeutics Inc. (NASDAQ:XRTX) (CVE:XRTX) Dr. Allen Davidoff-Look for ... - ABN Newswire
Mon, 08 Apr 2024
XORTX Welcomes New Member to the Board of Directors - WDRB
Tue, 19 Mar 2024
XORTX Therapeutics Advances Kidney Disease Program - TipRanks.com - TipRanks
Tue, 19 Mar 2024
XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 4 (%) |
| Held by Institutions | 23.9 (%) |
| Shares Short | 21 (K) |
| Shares Short P.Month | 2 (K) |
| EPS | -3.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.31 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -34.8 % |
| Return on Equity (ttm) | -37.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.69 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.72 |
| PEG Ratio | 0 |
| Price to Book value | 1.11 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|